Key points are not available for this paper at this time.
This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone.
Rodriguez et al. (Tue,) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: